{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:16:50Z","timestamp":1777529810968,"version":"3.51.4"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1097\/md.0000000000005456","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T23:23:45Z","timestamp":1484177025000},"page":"e5456","source":"Crossref","is-referenced-by-count":16,"title":["The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia"],"prefix":"10.1097","volume":"96","author":[{"given":"Tarek","family":"Owaidah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulkareem Al","family":"Momen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazzaa","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Almusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fawaz","family":"Alkasim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Tarawah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randa Al","family":"Nouno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima Al","family":"Batniji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Alothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saud","family":"Abu-Herbish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Abu-Riash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khawar","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansor","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SY","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahasen","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210309","first-page":"270","article-title":"Molecular basis of hemophilia","volume":"27","author":"Furie","year":"1990","journal-title":"Semin Hematol"},{"key":"R2-3-20210309","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1111\/j.1365-2516.2009.02100.x","article-title":"Cost of care of haemophilia with inhibitors","volume":"16","author":"Di Minno","year":"2010","journal-title":"Haemophilia"},{"key":"R3-3-20210309","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2516.2011.02623.x","article-title":"The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis","volume":"18","author":"Pokras","year":"2012","journal-title":"Haemophilia"},{"key":"R4-3-20210309","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2141.2004.05168.x","article-title":"Inhibitors in congenital coagulation disorders","volume":"127","author":"Key","year":"2004","journal-title":"Br J Haematol"},{"key":"R5-3-20210309","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"R6-3-20210309","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1538-7836.2012.04705.x","article-title":"Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance","volume":"10","author":"Miller","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R7-3-20210309","first-page":"260","article-title":"Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay","volume":"30","author":"Kim","year":"2010","journal-title":"Korean J Lab Med"},{"key":"R8-3-20210309","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-1-62703-339-8_24","article-title":"Nijmegen-Bethesda assay to measure factor VIII inhibitors","volume":"992","author":"Duncan","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R9-3-20210309","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1055\/s-0038-1648507","article-title":"Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group","volume":"67","author":"Sultan","year":"1992","journal-title":"Thromb Haemost"},{"key":"R10-3-20210309","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2516.2010.02231.x","article-title":"Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"key":"R11-3-20210309","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2516.2006.01261.x","article-title":"Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia","volume":"12","author":"Astermark","year":"2006","journal-title":"Haemophilia"},{"key":"R12-3-20210309","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1365-2516.2009.02058.x","article-title":"Risk factors for inhibitor formation in haemophilia: a prevalent case-control study","volume":"15","author":"Ragni","year":"2009","journal-title":"Haemophilia"},{"key":"R13-3-20210309","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R14-3-20210309","doi-asserted-by":"crossref","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","article-title":"Limitations and strengths of spontaneous reports data","volume":"20","author":"Goldman","year":"1998","journal-title":"Clin Ther"},{"key":"R15-3-20210309","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/hae.12302","article-title":"A study of prospective surveillance for inhibitors among persons with haemophilia in the United States","volume":"20","author":"Soucie","year":"2014","journal-title":"Haemophilia"},{"key":"R16-3-20210309","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.281.9.824","article-title":"Postmarketing surveillance and adverse drug reactions: current perspectives and future needs","volume":"281","author":"Brewer","year":"1999","journal-title":"JAMA"},{"key":"R17-3-20210309","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1046\/j.1538-7836.2003.0468a.x","article-title":"Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients","volume":"1","author":"Roussel-Robert","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R18-3-20210309","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1046\/j.1537-2995.1995.35795357875.x","article-title":"The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates","volume":"35","author":"Walker","year":"1995","journal-title":"Transfusion"},{"key":"R19-3-20210309","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/j.1365-2516.2011.02694.x","article-title":"Low prevalence of inhibitor antibodies in the Canadian haemophilia population","volume":"18","author":"Webert","year":"2012","journal-title":"Haemophilia"},{"key":"R20-3-20210309","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.12229","article-title":"Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database","volume":"20","author":"Puetz","year":"2014","journal-title":"Haemophilia"},{"key":"R21-3-20210309","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","article-title":"F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity","volume":"18","author":"Miller","year":"2012","journal-title":"Haemophilia"},{"key":"R22-3-20210309","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2516.2010.02422.x","article-title":"Treatment related factors and inhibitor development in children with severe haemophilia A","volume":"17","author":"Maclean","year":"2011","journal-title":"Haemophilia"},{"key":"R23-3-20210309","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2516.2006.01373.x","article-title":"Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development","volume":"12","author":"Ettingshausen","year":"2006","journal-title":"Haemophilia"},{"key":"R24-3-20210309","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","article-title":"Inhibitors occur more frequently in African-American and Latino haemophiliacs","volume":"4","author":"Aledort","year":"1998","journal-title":"Haemophilia"},{"key":"R25-3-20210309","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/j.1365-2516.2011.02739.x","article-title":"Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database","volume":"18","author":"Carpenter","year":"2012","journal-title":"Haemophilia"},{"key":"R26-3-20210309","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"R27-3-20210309","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/j.1538-7836.2006.02233.x","article-title":"Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates","volume":"4","author":"Kempton","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R28-3-20210309","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2516.2010.02430.x","article-title":"Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE\u00ae)","volume":"17","author":"Bacon","year":"2011","journal-title":"Haemophilia"},{"key":"R29-3-20210309","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2516.2010.02428.x","article-title":"Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate\u00ae: interim report from an ongoing prospective clinical study","volume":"17","author":"Klukowska","year":"2011","journal-title":"Haemophilia"},{"key":"R30-3-20210309","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2516.2011.02599.x","article-title":"An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan","volume":"17","author":"Shirahata","year":"2011","journal-title":"Haemophilia"},{"key":"R31-3-20210309","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10245330701255205","article-title":"Coagulation disorders and inhibitors of coagulation in children from Mansoura, Egypt","volume":"12","author":"Abdelrazik","year":"2007","journal-title":"Hematology"},{"key":"R32-3-20210309","first-page":"659","article-title":"Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs","volume":"70","author":"Kraiem","year":"2012","journal-title":"Ann Biol Clin (Paris"},{"key":"R33-3-20210309","first-page":"289","article-title":"Frequency of factor VIII (FVIII) inhibitor in haemophilia A","volume":"22","author":"Borhany","year":"2012","journal-title":"J Coll Physicians Surg Pak"},{"key":"R34-3-20210309","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/10245330600667526","article-title":"Pattern of factor VIII inhibitors in patients with hemophilia A in the north east of Iran","volume":"11","author":"Modaresi","year":"2006","journal-title":"Hematology"},{"key":"R35-3-20210309","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12288-014-0342-z","article-title":"The epidemiology of FVIII inhibitors in Indian haemophilia A patients","volume":"30","author":"Pinto","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R36-3-20210309","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1538-7836.2004.00729.x","article-title":"Is the incidence and prevalence of inhibitors greater with recombinant products? No","volume":"2","author":"Lusher","year":"2004","journal-title":"J Thromb Haemost"},{"key":"R37-3-20210309","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.moh.0000239702.40297.ec","article-title":"Risk of inhibitors in haemophilia and the type of factor replacement","volume":"13","author":"Goudemand","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"R38-3-20210309","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2516.2006.01338.x","article-title":"Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy","volume":"12","author":"Peerlinck","year":"2006","journal-title":"Haemophilia"},{"key":"R39-3-20210309","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.thromres.2013.10.017","article-title":"Inhibitors and prophylaxis in paediatric haemophilia patients: focus on the German experience","volume":"134","author":"Kurnik","year":"2014","journal-title":"Thromb Res"},{"key":"R40-3-20210309","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/hae.12136","article-title":"Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy","volume":"19","author":"Mondorf","year":"2013","journal-title":"Haemophilia"},{"key":"R41-3-20210309","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1538-7836.2009.03650.x","article-title":"Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R42-3-20210309","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MBC.0b013e328329e456","article-title":"Molecular genotyping of hemophilia A in Saudi Arabia: report of 2 novel mutations","volume":"20","author":"Owaidah","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R43-3-20210309","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2003-37936","article-title":"The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development","volume":"29","author":"Goodeve","year":"2003","journal-title":"Semin Thromb Hemost"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000005456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T09:57:08Z","timestamp":1749895028000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201701130-00003"}},"subtitle":["Results from the Saudi national hemophilia screening program"],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005456","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}